RxDoctor Payments Data

Saeid Karandish, MD

Internal Medicine · Encino, CANPI 1528419710

Payments from drug & device makers

$2,592in general payments, 2019–2025

Across 43 payments — averaging $60.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$408
  • AstraZeneca$327
  • Johnson & Johnson$307
  • Acadia Pharmaceuticals Inc$246
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$180
  • Avadel CNS Pharmaceuticals, LLC$143
  • plus $980 from 13 others

What the payments were for

  • Food & beverage$2,592100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,592 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$602,775
Medicare patients
365
Services billed
10,601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide103$98,890
MounjaroTirzepatide82$88,355
Metformin Er GastricMetformin Hcl12$16,277
LinzessLinaclotide22$11,958
FarxigaDapagliflozin Propanediol13$11,857
MyrbetriqMirabegron20$10,319
Diclofenac Sodium17$9,994
JanuviaSitagliptin Phosphate14$8,554
Rosuvastatin Calcium89$961
Acetazolamide13$677
Famotidine26$448
Minoxidil46$282
Losartan Potassium29$222
Memantine Hcl18$183
Azithromycin35$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$125$11,95822 claims
AstraZenecaFarxiga$327$11,85713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Encino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →